Navigation Links
Inspire Announces Presentations at 2007 Association for Research in,Vision and Ophthalmology Annual Meeting

sters can be downloaded from Inspire's website, www.inspirepharm.com, following the conclusion of the conference. Additional information related to the ARVO conference can be obtained at www.arvo.org.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM)(azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Forward-Looking Statements

The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further i
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Presentations at Two European Scientific Conferences
3. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

Post Your Comments:
(Date:12/1/2009)... Sleep Solutions®, Inc. (SSI),...testing and evaluation of sleep-disordered breathi...M.D., as its chief executive officer. Hassett was...ing its growth from a $250 million healthcare hold... total population health, and its subsequent sale ...
(Date:12/1/2009)...wswire/ -- At this year,s annual meeting of the Ra...Philips Electronics ( PHG, AEX: PHI) will introduc...s that provides radiologists the ability to review...elp drive quality and efficiency. Showcasing its ...ight new capabilities for its portfolio of diagnos...
(Date:12/1/2009)... Exagen Diagnostics, Inc., a molec...ps and markets proprietary genomic tests, today an... of the company,s board of directors and chief exe...nn was managing partner of Windamere Venture Partn...al companies including Prometheus Laboratories, Sa...
Breaking Medicine Technology:Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 4Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 2The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit 3B State Investigation Finds Evidence of Negligence at Woodbridge Day School 60768 1The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit 3B State Investigation Finds Evidence of Negligence at Woodbridge Day School 60768 2Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co Biomaster Inc 60766 1Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co Biomaster Inc 60766 2Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co Biomaster Inc 60766 3Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co Biomaster Inc 60766 4Qualsecs Wholly Owned Subsidiary Receives Order From New Jersey Based DMC Athletics and Rehabilitation 60764 1Qualsecs Wholly Owned Subsidiary Receives Order From New Jersey Based DMC Athletics and Rehabilitation 60764 2
...orporated (Nasdaq: VICL ),today is presenting exp...strating that the company,s Vaxfectin(R) adjuvant ...d infectious disease vaccines and,peptide-based ca...Vical,s,Senior Vice President of Product Developme... 8, at the World Vaccine Congress (Lyon, France - ...
...ealth Care and its Great,Lakes Cancer Institute ar...nds to share the latest work underway around the g...nts. The October 11th symposium, hosted by,McLaren..., M.D., an,award-winning surgical oncologist whose...er has gained worldwide recognition and has evolve...
Other Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2
(Date:12/1/2009)...est rates seen in Central and South America, study...ws) -- About 50 percent of intensive care unit pat...their risk of dying in the hospital, a new study f...a single day (May 8, 2007) on 13,796 patients, age...y found that 51 percent of patients were classifie...
(Date:12/1/2009)...ILADELPHIA (December 1, 2009) Wistar Institute r...f Pennsylvania and New York University have identi...cate early-stage lung tumors in people at high ris...hed online December 1 in Cancer Research , a jour...h, could lead to a simple blood test to detect lun...
(Date:12/1/2009)... , RESEARCH TRIANGLE PARK, N.C., Dec. 1 /P...itiated in 2001 and have expanded over the years s...lly. The facility which was originally set up in a...armacy services, as part of the suite of services ... industry as a valuable offering. ,, The pharma...
(Date:12/1/2009)... , WASHINGTON, Dec. 1 /PRNewswire-USNewswire...CDHPs) are more likely than those with traditional...haviors, to be more engaged in wellness programs, ...centives matter in holding down costs, according t... Employee Benefit Research Institute (EBRI). ,...
(Date:12/1/2009)... , FORT LAUDERDALE, Fla., Dec. 1 /PRNewswir... patient enrollment in the randomized clinical tri...tent (Combo Stent). ,, A prospective, randomize... valuation of an ablu M inal sirolimus coat ED ...tients at up to 20 sites in Asia, Australia, Europ...
Breaking Medicine News(10 mins):Health News:Half of ICU Patients Suffer From Infections 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4
...l elections in US. The issue is raging in neighbou...ticians to get away with glib talk. As the country...quent on the governments commitment to medicare, a...s need a credit card'' and "Where did medicare go?...
...nxiously awaiting reports later this week on wheth...e deadly viral hemorrhagic septicemia. Of...rces (DNR) confirmed that two fish from an adjoini...ke Butte des Morts is the first occurrence of the ...
...pressed over the housing together of two convicted...rs Robbie Sebastian Wheeler, 43, and his boyfrien...ether in Hakea jail, in West Australia. The t...ed to murder the boy and dispose of his body. ...
...rculosis, researchers say. A study of 131 ...ity of the body to inhibit the growth of the bacte...f BBC News. Until now no study has evaluat...cipants and infected with mycobacteria. Th...
...udents with asthma who participated in a specially...ported fewer days and nights with symptoms, fewer...vity, and less hospitalization for asthma during a...gist for the Henry Ford Health System in Detroit, ...
...stroke in the past two months across Orissa, offic... been reported from the southern district of Ganja...icts of Balasore, Kandhamal, Kendrapada, Nuapada a... from various parts of the state. These are being ...
Other Medicine News:Health News:Cancer Patients Turn Their Backs on Canadian Health Minister 2Health News:Deadly Virus Hits Popular Lake in US 2Health News:Outrage Against Gay PartnersInCrime Kept Together 2Health News:Web-based Asthma Program Improves Disease Management for Black Students 2
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: